Welcome

Merck Pushes Ahead on Coronavirus Treatment, Vaccines

July 31, 2020, 4:13 PM

Merck & Co.plans to begin two large clinical trials in September of an experimental oral antiviral therapy for Covid-19, pushing ahead with efforts to bring another treatment option to market.

There is a “profound medical need for an orally active treatment,” Roger Perlmutter, the pharmaceutical giant’s top scientist, said Friday on Merck’s earnings conference call. The therapy, known as MK-4482, was discovered by scientists at Emory University and is being studied in phase 2 trials. If approved by regulators, it would compete with Gilead Sciences Inc’s remdesivir, which is administered intravenously and being evaluated as an inhaled spray....

To read the full article log in.

Learn more about a Bloomberg Law subscription.